Table 1 Baseline characteristics of the study population.
From: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Baseline characteristic | All patients (%), N = 5598 | Age <75 (%), N = 4806 (85.8) | Age ≥75 (%), N = 792 (14.1) | p value |
|---|---|---|---|---|
Centre | <0.01 | |||
USA | 4903 (87.6) | 4318 (89.8) | 585 (73.8) | |
Japan | 194 (3.5) | 108 (2.2) | 86 (10.9) | |
Milan, Italy | 168 (3.0) | 120 (2.5) | 48 (6.1) | |
UK | 113 (2.0) | 81 (1.7) | 32 (4.0) | |
South Korea | 97 (1.7) | 95 (2.0) | 2 (0.3) | |
Germany | 71 (1.3) | 53 (1.1) | 18 (2.3) | |
Novara, Italy | 52 (0.9) | 31 (0.6) | 21 (2.6) | |
Sex | <0.01 | |||
Male | 5402 (96.5) | 4667 (97.1) | 735 (92.7) | |
Female | 196 (3.5) | 139 (2.9) | 57 (7.2) | |
Risk factors for chronic liver diseasea | ||||
Hepatitis B infection | 395 (7.1) | 366 (7.6) | 29 (3.7) | <0.01 |
Alcohol relatedb | 2368 (43.8) | 2244 (47.8) | 124 (17.6) | <0.01 |
Hepatitis C infection | 2896 (51.7) | 2722 (56.6) | 174 (22.0) | <0.01 |
Otherc | 237 (4.3) | 156 (3.3) | 81 (10.3) | <0.01 |
Child–Turcotte–Pugh class | <0.01 | |||
A | 3281 (58.9) | 2754 (57.5) | 527 (67.0) | |
B | 2071 (37.2) | 1821 (38.0) | 250 (31.8) | |
C | 220 (3.9) | 211 (4.4) | 9 (1.1) | |
Maximum tumour diameter | <0.01 | |||
≤7 cm | 2236 (66.1) | 1914 (67.0) | 322 (60.9) | |
>7 cm | 1148 (33.9) | 942 (33.0) | 206 (39.0) | |
Portal vein thrombus | <0.01 | |||
Absent | 3633 (71.6) | 3070 (70.6) | 563 (77.9) | |
Present | 1441 (28.4) | 1281 (29.4) | 161 (22.1) | |
AFP (ng/dL) | 0.05 | |||
≤400 | 2523 (47.9) | 2160 (47.4) | 363 (51.5) | |
>400 | 2743 (52.1) | 2401 (52.6) | 342 (48.5) | |
Metastases | 0.3 | |||
Absent | 4381 (79.0) | 3778 (79.2) | 603 (77.5) | |
Present | 1168 (21.0) | 993 (20.8) | 175 (22.5) | |
Previous treatment | ||||
Resectiond | 125 (18.0) | 98 (20.1) | 27 (13.0) | 0.03 |
Radiofrequency ablation | 394 (7.0) | 319 (81.0) | 75 (19.0) | <0.01 |
Transarterial chemoembolisation | 792 (14.1) | 231 (14.6) | 561 (14.0) | 0.55 |
Y90 | 5 (0.1) | 5 (0.1) | 0 (0.0) | 0.41 |
Starting dose of sorafenib | 0.40 | |||
200/400 mg | 2095 (37.4) | 1788 (37.2) | 307 (38.8) | |
800 mg | 3503 (62.6) | 3018 (62.8) | 485 (61.2) |
